ERK2 activation in arteriolar and venular murine thrombosis: platelet receptor GPIb vs. P2X1

C. Oury,* 1 K. Daenens,* 1 H. Hu,* E. Toth-Zsamboki,* M. Bryckaert† and M. F. Hoylaerts*
*Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium; and †Hopital Lariboisière, U689 INSERM, IFR139, Paris, France


Summary. The functional significance of extracellular signal-regulated kinase 2 (ERK2) activation was investigated during shear induced human platelet aggregation (SIPA) in vitro and during shear controlled thrombosis in vivo in intestinal arterioles and venules of wild type (WT) and transgenic (TG) mice with platelet-specific overexpression of human P2X1 (TG). In SIPA, ERK2 was rapidly phosphorylated during GPIb stimulation, its activation contributing to SIPA for 50%, independently of P2X1 regulation. Thrombotic occlusion of injured arterioles occurred considerably faster in TG (4.3 ± 2.3 min) than in WT (38 ± 8 min) arterioles, but occlusion times in TG (19 ± 12) and WT (48 ± 4.5 min) venules differed less. Both the αβ3-meATP triggered desensitization of platelet P2X1, as well as P2X1 antagonism by NF279 or NF449 prolonged mean occlusion to about 75 min in WT and 65 min in TG arterioles, but venular occlusion times were less affected. Preventing ERK2 activation by U0126 prolonged occlusion times in TG (41 ± 10 min) and WT (51 ± 17) arterioles more than in TG (46 ± 5 min) and WT (56 ± 6 min) venules, uncovering a role for ERK2 in shear controlled thrombosis. Antagonism of GPIb by a recombinant murine von Willebrand factor (VWF)-A1 fragment prolonged occlusion times to comparable values, ranging from 55 to 58 min, both in TG and WT arterioles and venules. Further inhibition strategies, combining VWF-A1, U0126 and NF449 in WT and TG mice and resulting in occlusion in various time windows, identified that inhibition by VWF-A1 largely abrogated the ERK2 contribution to thrombosis. In conclusion, P2X1 and ERK2 both participate in shear stress controlled thrombosis, but ERK2 activation is initiated predominantly via GPIb–VWF interactions.

Keywords: degranulation, nucleotides, platelet, shear stress, signaling, thrombosis.

Introduction

Upon blood vessel injury, circulating platelets tether to the vessel wall, form a plug and arrest bleeding [1]. Platelets interact with subendothelial von Willebrand factor (VWF) via platelet glycoprotein Ibα (GPIbα) and with collagen fibers via platelet GPVI and α2b1 [2–5]. Adhering platelets undergo morphological changes, synthetize thromboxane A2 (TxA2), secrete ATP and ADP from dense granules and several proteins from α-granules [6], each of them interacting with specific platelet receptors and leading to further recruitment and activation of platelets [7–9], processes exacerbated during atherothrombotic disease [10].

Platelets express three known P2 receptors for adenine nucleotides: the GTP binding protein-coupled P2Y1 and P2Y12 receptors, activated by ADP, and the ATP-gated P2X1 ion channel [11,12]. Gq-coupled P2Y12 plays a central role in platelet activation and is a pharmacological target for P2Y12 antagonists [13] and thienopyridines [14]. Studies in P2Y12-deficient mice revealed that this receptor is involved in thrombus growth and stability and that its gene deficiency markedly impacts on thrombosis [15]. Gq-coupled P2Y1 is also involved in thrombus growth and its antagonism in mice has equally proven to be antithrombotic [16]. Overexpression of P2X1 ion channels in the megakaryocytic cell lineage of transgenic (TG) mice generates a prothrombotic phenotype [17]. That study and analysis of platelet function in P2X1-null mice [18] indicated that P2X1 contributes to thrombus formation, particularly in conditions in which shear forces are high. Notably, in P2X1-null mice, the size of mural thrombi formed after laser-induced arterial wall injury was decreased and the time for complete thrombus removal was shortened [18].
Via the influx of Ca\(^{2+}\), platelet P2\(X_1\) mediates activation of the extracellular signal-regulated kinase 2 (ERK2), an event participating in platelet aggregation induced by low concentrations of collagen [19,20]. Accordingly, inhibition of ERK2 activation by the MAPK kinase inhibitor U0126 could considerably reduce mortality in a model of collagen-induced pulmonary embolism, in P2\(X_1\) overexpressing TG and in wild type (WT) mice [17]. More recently, we reported a role for P2\(X_1\) in shear stress induced platelet activation [21], but also found that the adhesion of platelets to collagen, following perfusion under shear stress conditions involved ERK2 phosphorylation, a process dependent on platelet-VWF interactions [22]. In addition, it has been shown that in platelets, ERK2 is also activated by thrombin [23,24], a process recently having been linked to ADP secretion and subsequent P2\(Y_{12}\) receptor signaling [25].

In view of the role of the P2\(X_1\)-ERK2 axis in shear stress-independent platelet activation by collagen, in the present study, we therefore set out to investigate the role of shear stress-dependent ERK2 activation in platelets in vitro and in vivo in a mouse model of arteriolar and venular thrombosis in WT mice, and in mice specifically overexpressing human P2\(X_1\) in platelets [17]. We confirmed that P2\(X_1\) functions in shear stress controlled thrombosis, to a larger degree in arteriolar than venular thrombosis. Moreover, we identified a role for ERK2 activation in arteriolar and venular thrombosis in both WT and TG mice, its contributions to shear stress controlled thrombosis, however, relying largely on GPI\(b\)-VWF initiated signaling, rather than on P2\(X_1\)-ATP signaling.

Materials and methods

Materials

The P2\(X_1\) agonist \(\alpha,\beta\)-methylene adenosine 5'-triphosphate (\(\alpha,\beta\)-meATP), the P2\(X_1\)/P2\(X_3\) agonist L-\(\beta,\gamma\)-methylene adenosine 5'-triphosphate (L-\(\beta,\gamma\)-meATP) and the ectonucleotidase apyrase (grade I) were purchased from Sigma (St Louis, MO, USA). Clopidogrel (Plavix, Sanofi, Toulouse, France) was also obtained from Sigma (St Louis, MO, USA). Sodium, calcium and potassium chloride, Tris-HCl, HEPES and DTT were obtained from Sigma, and the molecular weight standards and Amersham proteins were obtained from Pharmacia Biotech (Uppsala, Sweden). Mouse albumin and 0.1 U mL\(^{-1}\) apyrase were purchased from local hospital pharmacy.

Preparation and labeling of washed mouse platelets

Washed mouse platelets were resuspended in Ca\(^{2+}\)-free Tyrode’s buffer (12 mM NaHCO\(_3\), 0.42 mM NaH\(_2\)PO\(_4\), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl\(_2\), 5 mM HEPES, 5.5 mM glucose, 0.35% human serum albumin and 0.1 U mL\(^{-1}\) apyrase).

Light transmission during collagen induced platelet aggregation in murine PRP was recorded with a Chrono-Log Aggregometer. At least three independent experiments were performed on PRP from different pools.

Shear stress induced platelet aggregation and perfusion studies

Aggregation of washed human platelets in shear stress conditions (shear induced platelet aggregation, SIPA) was carried out in a laminar shear generator, as previously described [21]. The U0126 used during SIPA was dissolved in dimethyl sulfoxide (DMSO) at 10 mM and then diluted 100-fold in saline, and further in Tyrode’s buffer, containing 0.35% human serum albumin and 0.42 mM NaH\(_2\)PO\(_4\).

Immunoblotting

Platelets (0.3 mL of platelet suspensions) were lysed in sodium dodecyl sulfate (SDS) sample buffer (62.5 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 50 mM DTT, 0.1% bromophenol blue). Sample aliquots were loaded on SDS-polyacrylamide gel electrophoresis (12.5%) and subjected to Western blotting.
ERK2 and phospho-ERK2 were detected, using the PhosphoP-Plus p44/42 MAP Kinase Antibody kit (New England Biolabs UK Ltd, Hitchin, UK) according to the instructions of the manufacturer. Densitometric band scanning was performed, using Image J (NIH, Bethesda, MD, USA).

**Photochemically induced thrombosis (PIT)**

All animal experiments were reviewed and approved by the Institutional Review Board of the University of Leuven and were performed in compliance with the guidelines of the International Society on Thrombosis and Haemostasis [32]. FVB WT and TG mice (8 to 12 weeks old) were anesthetized with pentobarbital (25–35 mg kg⁻¹ intraperitoneally) and the jugular vein was catheterized with a 2.5 Fr canule. Mice were positioned on a translucent table of an inverted epifluorescence microscope (Diaphot; Nikon, Melville, NY, USA) and the intestines were exposed such that the arterioles and venules covering the cecum were visualized through a Cohu CCD video camera (COHU Inc, San Diego, CA, USA). Via the jugular vein catheter, a bolus of rose bengal was injected (20 mg kg⁻¹), followed by injection of fluorescently labeled murine platelets (0.5 × 10⁶ platelets µL⁻¹ in 200 µL) and perfusion of rose bengal (20 mg kg⁻¹ h⁻¹) during 30 min, the time required for the injected platelets to reach steady-state. Selected arterioles/venules were exposed for 40 s to green light, focused through the microscope objective (40 × magnification), resulting in localized and reproducible vessel wall injury over a distance of about 500 µm. Recruitment of fluorescently labeled platelets to the lesion site (adhesion and aggregation) was observed in realtime, digitized with a Scion LG3 frame grabber (Scion Corp, Frederick, ML, USA) and recorded in the memory of an attached computer for later analysis with the NIH Image program version 6.1. The vessel occlusion time was defined as the moment of blood flow arrest due to an occlusive thrombus in the injured arteriole or venule, that is, with flow zero.

To study the consequences on thrombus development of various inhibitors of platelet function, a bolus perfusion of the inhibitors tested was applied through the catheterized jugular vein 5 min prior to vessel wall injury. The following inhibitors and doses were used: the selective P2X1 agonist NF279 (bolus 0.1 µmol kg⁻¹ = 80.8 µg kg⁻¹ + infusion at 80.8 µg kg⁻¹ h⁻¹), the selective P2X1 receptor antagonists NF279 (bolus 0.1 µmol kg⁻¹ = 150 µg kg⁻¹ + infusion 150 µg kg⁻¹ h⁻¹) and NF449 (bolus 0.1 µmol kg⁻¹ = 168.5 µg kg⁻¹ + infusion at 168.5 µg kg⁻¹ h⁻¹), the MEK1/2 inhibitor U0126 (bolus 0.53 µmol kg⁻¹ = 200 µg kg⁻¹ + infusion at 200 µg kg⁻¹ h⁻¹) and the murine GPIb antagonist VWF-A1 (bolus 0.04 µmol kg⁻¹ = 2000 µg kg⁻¹ + infusion at 2000 µg kg⁻¹ h⁻¹). When indicated, combined inhibitor treatments were performed. In addition, inhibition of the P2Y₁₂ antagonist with clopidogrel (Sanofi, Toulouse, France), applied intragastrically at a dose of 20 mg kg⁻¹ 24 h before analyses, was performed to evaluate the impact of interference with P2 receptors via ADP-mediated platelet activation on our thrombosis model.

**Expression and purification of glutathion-S-transferase-mouse VWF-A1 fusion protein**

The glutathion-S-transferase-mouse VWF A1 domain fusion protein were produced via RT-PCR from mouse platelet RNA extracts, using the following primers: forward: GTT GGA TCC ACC CCC GAG CCC CCC CTG CAC, introducing a 5’ BamHI site; reverse: AT GTT CGA CCG TTT TGG TCC CGG TGA CGA, introducing a 3’ SalI site. PCRs were carried out in a PTC-100 Programmable Thermal Controller (MJ Research, Inc. Watertown, MA, USA) as described before for the production of glutathion-S-transferase-human VWF-A1 domain fusion proteins [30]. The PCR product was then digested by BamHI and SalI, and inserted into the pGEX4T-2 vector containing the DNA sequence for GST (Amersham Pharmacia Biotech, Roosendaal, The Netherlands), and cloned [30]. Hence, a 693 bp fragment was inserted, spanning the murine A1 domain between amino acid residue Thr499 and Arg729, in traditional human residue number counting. The fusion protein expression was induced with 500 µM isopropyl-B-D-thiogalactopyranoside (IPTG) in Escherichia coli bacteria and the recombinant protein (VWF-A1) was purified on GST-beads, as described [30].

**Statistical analysis**

Comparisons between vessel occlusion times were made via two-sample test comparison, using Mann–Whitney statistical tests, described by 2-tailed P values. P < 0.05 was considered to be statistically significant.

**Results**

**ERK2 activation in SIPA is not coupled to P2X₁**

We showed earlier that SIPA strongly depends on GPIb-VWF interactions, as well as on amplification reactions by platelet released nucleotides [21]. Fig. 1A shows that the P2X₁ agonist L-β,γ-meATP, added just prior to initiation of SIPA, rapidly accelerated platelet aggregation at high shear rates (9000 s⁻¹). However, L-β,γ-meATP also potentiated the weak platelet aggregation observed at low shear rates (1000 s⁻¹). Figure 1B shows that at 9000 s⁻¹, SIPA was accompanied by rapid ERK2 phosphorylation in platelets, maximal at 60 s. The ERK2 phosphorylation was reversible and had completely disappeared at 3 min. Integrated density analysis (Fig. 1B) of phospho-ERK2 at 60 s revealed that the mean degree of ERK2 phosphorylation was unaffected by pre-incubation with L-β,γ-meATP, despite persistent elevation of the degree of SIPA, up to 3 min during pretreatment with L-β,γ-meATP (Fig. 1A).

Recently, we demonstrated that shear stress controlled adhesion of platelets to collagen, involves activation of ERK2 in a VWF dependent manner [22]. We therefore investigated, whether, during SIPA, P2X₁ was functionally coupled to ERK2 activation. Figure 1C shows, indeed, that inhibition of ERK2 activation with the MAPK kinase inhibitor
finding contrasted with the P2X₁-ERK2 coupling during collagen-induced platelet activation in the absence of shear stress [17,19] and advocated further investigations of ERK2 in shear controlled platelet activation in vivo.

Inhibition of platelet aggregation by P2X₁ antagonists

Prior to in vivo studies, NF449 and NF279, both suramin analogs, exhibiting high potency in inhibiting P2X₁ in other systems and highly selective over other P2X ion channels and P2Y receptor inhibitors [26,33], were tested in platelet aggregation. Low concentrations of NF279 substantially inhibited the collagen-induced aggregation of human (not shown) and of murine WT platelets (Fig. 2A), at least when aggregation was induced at collagen concentrations below 0.5 µg mL⁻¹, in agreement with the known function of P2X₁ in low-dose collagen-induced platelet aggregation [28]. When P2X₁ was desensitized via pretreatment of platelets with α,β-γ-meATP, the subsequent collagen-induced aggregation was no longer affected by NF279 (data not shown), confirming the specificity of P2X₁ inhibition by NF279 during aggregation. When tested in the presence of low concentrations of apyrase, to more optimally preserve P2X₁ function, NF449 potently inhibited

U0126 reduces SIPA to 50%. In the presence of 0.5 U mL⁻¹ apyrase, i.e. at a concentration that degrades ATP and ADP partially, to a degree that eliminates contributions to SIPA of ATP-P2X₁ and ADP-P2Y₁ interactions, without abolishing ADP-P2Y₁₂ interactions [21]. U0126 still caused 50% inhibition of SIPA (Fig. 1C). Even when P2X₁ was stimulated with the apyrase resistant L-β,γ-meATP, just prior to SIPA, such treatment enhanced SIPA but did not affect the degree of SIPA inhibition by U0126 (Fig. 1C). These results illustrated, although ERK2 activation could be influenced by P2X₁ activation, that its role in SIPA was not coupled to P2X₁, although being coupled to GPIb-VWF (Fig. 1B) [21,22].

![Fig. 1. ERK2 activation is SIPA is unrelated to P2X₁ stimulation. (A) Representative example of the degree of washed human platelet aggregation, without apyrase, at the indicated shear rate of 1000 or 9000 s⁻¹, as a function of time, in the absence or presence of L-β,γ-meATP (10 µM), added immediately prior to SIPA. (B) Western blot of total ERK2 (lower bands) and P-ERK2 (upper bands) during SIPA for the indicated time points, at 1000 or 9000 s⁻¹, bands) and P-ERK2 (upper bands) during SIPA for the indicated time points, at 1000 or 9000 s⁻¹, and with or without specific P2X₁ stimulation with L-β,γ-meATP (10 µM), added immediately prior to SIPA; integrated mean (+ SD) band intensities for P-ERK2, at 60 s (n = 3), in the absence or presence of L-β,γ-meATP and compared with the averaged resting platelet P-ERK2 intensity (0 s, AU; arbitrary units). (C) Degree of washed human platelet aggregation induced at 9000 s⁻¹ for 3 min, in the absence or presence of U0126 (1 µM) as indicated; the presence of apyrase (0.5 U mL⁻¹) in the platelet suspension is represented by the long horizontal line; specific P2X₁ stimulation with L-β,γ-meATP (10 µM), added immediately prior to SIPA is indicated via the short horizontal line. (*P < 0.005 vs. corresponding control without inhibition, †P < 0.005 vs. 9000 s⁻¹, P = 0.001 vs. 9000 s⁻¹ + apyrase). Experiment number ranges from three (U0126 inhibition) to nine (respective controls).](image1)

![Fig. 2. P2X₁ antagonism during collagen-induced aggregation. (A) Aggregation tracings of WT mouse hirudinized, apyrase-free platelet-rich plasma by the indicated concentration of collagen, in the presence or absence of NF279 (1 µM). (B) Aggregation of WT mouse hirudinized, platelet-rich plasma by collagen (0.2 or 0.3 µg mL⁻¹, as indicated) or ADP, in the presence or absence of 0.1 U mL⁻¹ apyrase and NF449 (0.3, 10 or 20 µM), as indicated. (C) Aggregation of TG mouse hirudinized, platelet-rich plasma by collagen, in the presence of 0.1 U mL⁻¹ apyrase and NF279 (1 µM) or NF449 (1 or 10 µM, as indicated, or 1 µM in the right panel).](image2)
the low dose collagen-induced platelet aggregation of WT platelets, as recently reported [33] and as potently as NF279 (Fig. 2B). When tested in apyrase-free platelet-rich plasma, higher concentrations of NF449 were required to inhibit the collagen-induced platelet aggregation. Nevertheless, aggregation of WT mouse PRP by 5 or 7.5 μM ADP was not inhibited at these concentrations of NF449 (Fig. 2B). Likewise, NF279 and NF449 inhibited the weak aggregation of murine TG platelets, overexpressing human P2X1, but not the stronger aggregation, induced by slightly higher collagen concentrations (Fig. 1C). These findings illustrate that NF279 and NF449 reduced platelet aggregation by collagen in PRP, in a manner formally similar to P2X1 desensitization with α,β-meATP [28], enabling their use for the in vivo study of thrombosis, i.e. when tested at low plasma concentrations, thus avoiding interference of the ADP mediated activation of P2Y1 [33].

Arteriolar and venular thrombosis in WT and TG mice

To study the role of platelet P2X1 and ERK2 in shear stress-controlled thrombosis in vivo, we used a model of photochemical blood vessel injury in WT and TG mice, focusing both on arteriolar and venular thrombosis. Thrombus formation was constantly monitored microscopically in real time until vessel occlusion. Figure 3A shows a series of chronological images of developing thrombosis in the arteriolar and venular circulation of WT and TG mice. To characterize contributions to thrombosis of P2X1 vs. the central role of P2Y12 in platelet activation amplification [15], mice were also treated with clopidogrel. This treatment strongly delayed arteriolar vessel occlusion (WT: 38 ± 8 min, n = 13; WT + clopidogrel: 102 ± 1 min, n = 3; values: mean ± SD, P < 0.01) (not shown), confirming that P2Y12, activated by released ADP, is instrumental in this thrombosis model. TG mice showed nearly immediate arteriolar vessel occlusion following photochemical injury (Fig. 3A), corroborating our previous findings [17] that P2X1 overexpression promotes thrombosis. Nevertheless, treatment of TG mice with clopidogrel strongly inhibited thrombus formation (arteriolar vessel occlusion time = 99 ± 7.8 min, n = 3, P = 0.015, not shown), which therefore still largely depended in TG mice on P2Y12.

To neutralize VWF in the mouse, a recombinant mouse VWF A1 domain (VWF-A1) was produced and validated in vitro and in vivo. During perfusion studies of calcein-labeled platelets over glass surface coated VWF-A1, platelet rolling was supported at a shear rate of 600 s⁻¹, but not 300 s⁻¹ (not shown); this interaction was inhibited by soluble VWF-A1, added to the perfusate, as a consequence of competition with surface coated VWF-A1 for binding to platelet GPIb (Fig. 3B). Further in vivo validation during the recording of platelet tethering over A23187 activated endothelium of mouse mesenteric blood vessels, confirmed that, in mice, VWF-A1 was capable of reducing the VWF mediated rolling of circulating platelets over A23187 activated endothelial cells (Fig. 3C). This fragment was therefore selected to pharmacologically inhibit VWF during our thrombosis studies.

Importance of P2X1 activity in arteriolar and venular thrombosis

In vivo desensitization of P2X1 in WT mice by an i.v. bolus of α,β-meATP, followed by a continuous infusion, aiming to achieve an initial plasma concentration of 2 μM, prior to injury induction delayed arteriolar vessel occlusion from 38 ± 8 min to 74 ± 2 min. An i.v. bolus of NF279, followed by an infusion, aiming to achieve an initial plasma concentration of 1.25 μM, likewise, delayed arteriolar vessel occlusion to 75 ± 10 min. An i.v. bolus of NF449, followed by an infusion, aiming to equally achieve an initial plasma concentration of 1.25 μM, delayed arteriolar vessel occlusion to 79 ± 6 min (Fig. 4A). The identical treatments of TG mice with α,β-meATP delayed occlusion from 4.3 ± 2.3 min to 68 ± 3.1 min, with NF279 to 60 ± 6.7 min and with NF449 to 68 ± 2.6 min. Taken together, these data demonstrate that platelet P2X1 is involved in the regulation of arterial thrombosis and underscore that the pharmacological inhibition of P2X1 by low plasma concentrations of NF279 or NF449 is equipotent in WT and TG mice. Furthermore, P2X1 inhibition and inactivation via desensitization with its agonist α,β-meATP reduce the role of P2X1 in thrombosis to the same degree.

Whereas overexpression of P2X1 in TG mice strongly shortened arteriolar occlusion times, it affected venular occlusion times more weakly (19 ± 12 min), compared with the WT control values (48 ± 4.5 min; Fig. 4B). Correspondingly, α,β-meATP, NF279 and NF449 only moderately affected venular occlusion times in WT mice to 66 ± 10, 56 ± 10 and 70 ± 5.3 min respectively. In TG mice, as expected, more pronounced inhibition was noted, however to comparable occlusion times, averaging 69 ± 7, 52 ± 15 and 64 ± 2.2 min in α,β-meATP, NF279 and NF449 treated mice, respectively. These findings illustrate that shear stress is a crucial component of P2X1 regulation in vivo.

Pooled analysis in venular thrombosis for WT and TG mice revealed a mean occlusion time (67 ± 8.4 min, n = 10) during desensitization with α,β-meATP, identical to the mean occlusion time (67 ± 5 min, n = 8), achieved during antagonism with NF449. These values are significantly longer than the mean occlusion time (54 ± 12 min, n = 8) during treatment with NF279 (P < 0.05). Therefore, low concentrations of NF449 appeared more potent than NF279, motivating its further selection as an inhibitor to neutralize P2X1 function.

ERK2 phosphorylation is involved in arteriolar thrombosis

Platelet aggregation by VWF (induced via ristocetin) involves ERK2 activation and VWF binding to GPIbα causes phosphorylation of ERK2 [34]. Because we found shear stress dependent ERK2 phosphorylation to be coupled to VWF binding to GPIbα during platelet-collagen interactions [22], but not to P2X1 (Fig. 1), the role of the ERK2 pathway in arteriolar vs. venular thrombosis was investigated, via administration of that dose of U0126, known to prevent
mortality in an experimental model of pulmonary thromboembolism, partially in WT mice and completely in TG mice [17]. Figure 5 shows how the mean arteriolar vessel occlusion time is moderately, but significantly prolonged in WT mice by U0126 to 51 ± 17 min. Nevertheless, the vessel occlusion time distribution ranged from 19 to 64 min (n = 11), compared with a vessel occlusion time distribution, ranging from 21 to 48 min in non-treated controls (n = 13). This finding suggested a moderate and variable role for ERK2 during platelet activation, involved in most, but not all animals. However, the narrower arteriolar occlusion time distribution in TG mice, as well as the significant arteriolar vessel occlusion prolongation by U0126 to 41 ± 10 min provided evidence for a role for ERK2 activation in thrombosis in TG mice. Venular occlusion times, on the contrary, were weakly affected by U0126 treatment in WT (56 ± 6.1 min) mice, but appeared still prolonged in TG mice (46 ± 5.3 min). These findings uncovered a more important role for ERK2 in arteriolar than in venular thrombosis, but did not allow distinction between VWF
dependent vs. P2X₁ mediated ERK2 activation in the TG mice. Nevertheless, no significant differences were found between occlusion times in U0126 treated WT and TG mice, neither for arteriolar, nor for venular comparisons.

**ERK2 activation in arteriolar thrombosis is coupled to GPIb activation**

To further investigate the respective role of GPIb and P2X₁ in ERK2 activation during thrombosis, its phosphorylation was blocked by U0126 in the context of GPIb inhibition and P2X₁ inhibition respectively, both in WT (Fig. 6) and TG mice (Fig. 7). The most striking finding of this analysis was that VWF inactivation by VWF-A1 resulted in very similar arteriolar occlusion times in WT (58 ± 7.4 min) and TG (56 ± 4.2 min) mice. Likewise, venular occlusion times were similarly prolonged in WT (55 ± 7 min) and TG (57 ± 4.6 min) mice, during treatment with VWF-A1 (Figs 6 and 7). The combined treatment with U0126 + VWF-A1 only mildly further prolonged arteriolar occlusion times in WT (68 ± 2.9 min) and TG (68 ± 2.2 min) mice, to identical values, compared with VWF-A1 treated mice (Figs 6 and 7). Likewise, combined treatment with U0126 + NF449 mildly prolonged arteriolar occlusion times in WT (84 ± 4.6 min) and TG (78 ± 3.3 min) mice, compared with NF449 treated mice (Figs 6 and 7).

The combined treatment with U0126 + VWF-A1 prolonged venular occlusion times in WT (74 ± 6.7 min) and TG (60 ± 4.8 min) mice, compared with VWF-A1 treated mice (Figs 6 and 7). Finally, the combined treatment with U0126 + NF449 clearly prolonged venular occlusion times in WT (84 ± 6.2 min) and TG (86 ± 3.2 min), compared with NF449 treated mice (Figs 6 and 7).

**Discussion**

Murine thrombosis depends on VWF-GP Ibα and VWF-αⅢbβ3 interactions [35], fibrinogen-αⅢbβ3 interactions [35] as well as on fibronectin-αⅢbβ3 interactions [36]. Secondary amplification pathways, involving P2Y₁ [11,16], P2Y₁₂ [14,15] and P2X₁ [18,33] are essential in controlling thrombus growth [13]. Also in the presently applied thrombosis model, clopidogrel behaves as a potent antithrombotic: a single dose strongly prevents vessel wall injury-triggered thrombus formation in arterioles and venules of the murine intestinal circulation. We therefore used this platelet-dependent model to evaluate the role of ERK2 in thrombosis, in relation to pathways studied before, such as activation of the GP Ib-VWF pathway [21,22] and P2X₁ mediated ERK2 activation occurring during the collagen-induced platelet aggregation [19,20]. Using TG mice overexpressing platelet human P2X₁, we confirm a role for P2X₁, which is more pronounced but not limited to high shear stress conditions. Hence, in TG mice, arteriolar thrombosis was more strongly intensified than venular thrombosis, compared with WT mice. Correspondingly, pharmacological inhibition of thrombosis by the P2X₁ antagonists NF279 and NF449 was
more pronounced in arteriolar than in venular thrombosis, but was operative in both. Desensitization of P2X<sub>1</sub> with α,β-meATP yielded similar inhibition of thrombosis as P2X<sub>1</sub> antagonism, adding to the specificity of NF449, at least when used at low concentrations. Moreover, the degree of inhibition of thrombosis in WT and TG mice by NF449 was comparable, compatible with saturated P2X<sub>1</sub> occupation at the dose regimen applied, also in TG mice.

Although not activated by ADP and its potent analogue 2-methylthio-ADP, platelet stimulation with thrombin induces ERK2 activation in a manner, highly dependent on ADP secretion and P2Y<sub>12</sub> receptor signaling [25]. These findings were explained via primary signaling through G<sub>q</sub> and subsequent coupling via Gi by the P2Y<sub>12</sub> receptor. Other reports have also demonstrated that a coordinated pathway through both G<sub>q</sub> from TxA<sub>2</sub> and Gi from ADP was necessary for ERK2 activation in vitro [37]. In view of the importance of ERK2 activation in controlling platelet aggregation by collagen [20], as well as in SIPA (this study), we presently studied further the importance of ERK2 activation during in vivo thrombosis, in relation to shear stress controlled signaling processes. The MEK 1/2 inhibitor, U0126, at a concentration blocking ERK2 activation, mildly prolonged arteriolar occlusion times in WT mice, but not all animals responded to this inhibitor. In contrast, a more homogeneous and clear prolongation of arteriolar occlusion times was found in TG mice, confirming a role in vivo for the ERK2 pathway. Similarly to the role of P2X<sub>1</sub> in thrombosis, ERK2 was found to be more important in arteriolar thrombosis, because in TG mice, the relative effect of U0126 was smaller on venular thrombosis, but U0126 reduced thrombosis to a similar degree in WT and TG venules.

We have shown before that inhibition of SIPA by GPIb or VWF neutralization leads to a twofold reduction in the extent of platelet dense granule release [21], hence reducing amplifi-

**Fig. 6.** Double inhibition strategy in WT mouse thrombosis. Representative dot plots of occlusion times in arterioles (A) and venules (B), during photochemically induced thrombosis. Occlusion times are for mice treated with U0126 (bolus 0.53 μmol kg<sup>-1</sup> + infusion 0.53 μmol kg<sup>-1</sup> h<sup>-1</sup>), with VWF-A1 (bolus 0.04 μmol kg<sup>-1</sup> + infusion 0.04 μmol kg<sup>-1</sup> h<sup>-1</sup>), alone or combined with U0126 and with NF 449 (bolus 0.1 μmol kg<sup>-1</sup> + infusion 0.1 μmol kg<sup>-1</sup> h<sup>-1</sup>), alone or combined with U0126; Control and U0126, respectively NF449 values are the same as in Figs 4 and 5; two-tailed P values were calculated via two-column Mann–Whitney comparison.

**Fig. 7.** Double inhibition strategy in TG mouse thrombosis. Representative dot plots of occlusion times in arterioles (A) and venules (B), during photochemically induced thrombosis. Occlusion times are for mice treated with U0126 (bolus 0.53 μmol kg<sup>-1</sup> + infusion 0.53 μmol kg<sup>-1</sup> h<sup>-1</sup>), with VWF-A1 (bolus 0.04 μmol kg<sup>-1</sup> + infusion 0.04 μmol kg<sup>-1</sup> h<sup>-1</sup>), alone or combined with U0126 and with NF 449 (bolus 0.1 μmol kg<sup>-1</sup> + infusion 0.1 μmol kg<sup>-1</sup> h<sup>-1</sup>), alone or combined with U0126; Control and U0126, respectively NF449 values are the same as in Figs 4 and 5; two-tailed P values were calculated via two-column Mann–Whitney comparison.
cation waves of platelet activation by secreted ADP and ATP. In addition, nucleotide antagonism also reduces platelet degranulation by about 30% [21]. Therefore, neutralization of the GPIb-VWF axis will strongly reduce nucleotide contributions to thrombosis, also in our in vivo model. This interpretation explains our present findings during inhibition of GPIb-VWF interactions by the recombinant murine VWF-A1 domain. This fragment is capable of competing with murine VWF for the recruitment of platelets, a phenomenon largely dependent on VWF [38]. The finding that VWF-A1 reduces the thrombotic response in WT and TG mice to comparable occlusion times, despite extra platelet activation and shorter occlusion times in non-treated TG mice, implies that inhibition by VWF-A1 abrogates both initial adhesion of platelets, as well as subsequent amplification pathways, under control of released ATP. Hence, the interpretation that GPIb-VWF interaction inhibition slows down platelet recruitment to the vessel wall, platelet degranulation and subsequent nucleotide activation amplification, is compatible with classical concepts of thrombus formation [1,2].

These findings therefore implicate that GPIb inactivation inhibits potential GPIb-, as well as P2X1 mediated contributions of ERK2 to thrombosis. In addition, the small differences in occlusion times during inhibition by VWF-A1 vs. U0126 + VWF-A1, measured in WT and TG mice, then reflect relatively minor contributions to thrombosis for GPIb-VWF independent ERK2 signaling, such as via Src kinase [39]. Also, although our thrombosis studies did not allow a formal distinction between a role for GPIb mediated or subsequent P2X1 mediated ERK2 signaling, SIPA in vitro identified that ERK2 was involved in shear induced platelet activation, but independently of P2X1. Hence, the more pronounced relative inhibition of thrombosis by U0126 in TG than in WT mice can then be explained by a comparable prevention of VWF mediated signaling in WT and TG mice and by the more pronounced consequences of this inhibition during secondary amplification in TG, compared with WT mice. In addition, comparison of occlusion times during inhibition by U0126 vs. U0126 + VWF-A1 in WT and TG mice, confirms the existence of ERK2 independent contributions to thrombosis by platelet GPIb activation. The relatively smaller prolongation of occlusion times by VWF-A1 in WT and TG venules than in arterioles can be explained by a smaller role for VWF in venular than in arteriolar thrombosis [40] and by a smaller response of platelet P2X1 in venules to an already reduced release of ATP.

We have shown before that P2X1 neutralization reduced SIPA about twofold in human platelet aggregation [21]. Presently, we observed that NF449 prolongs occlusion times in WT and even in TG mice to values, even slightly longer than found during VWF-A1 inhibition, indicative of potent inhibition of secondary platelet activation, even when the initial platelet recruitment on injured vessel walls is preserved, in the presence of NF449. Occlusion times were only mildly prolonged further in U0126 + NF449 treated mice, compared with NF449 treatment alone. The interpretation that ERK2 largely operates via GPIb mediated signaling, even during the inhibition by NF449 and the U0126 + NF449 combination, is supported in this set of experiments by analysis in WT mice of the delay in occlusion during treatment with NF449, in the absence or presence of ERK2 signaling. In WT arterioles NF449 treatment delays the mean occlusion by 41 min, from 38 to 79 min; during U0126 treatment, the mean occlusion time is delayed by 33 min from 51 to 84 min in U0126 + NF449 treated animals. Likewise, in WT venules, NF449 treatment delays the mean occlusion by 22 min, from 48 to 70 min; during U0126 treatment, the mean occlusion time is delayed by 28 min from 56 to 84 min in U0126 + NF449 treated animals. This comparison reveals that P2X1 in thrombosis acts independently of ERK2, inhibition of the latter having no effect on P2X1 in thrombosis.

Although previously, we have coupled the activation of ERK2 and P2X1 stimulation in the context of collagen-induced platelet activation, our present findings link ERK2 activation to VWF signaling. It therefore appears that in the present shear stress thrombosis model, collagen mediated ERK2 signaling, as found in static conditions [19], is not operational. Although, in the rose-bengal model studied, contributions of subendothelial collagen to thrombosis may be limited, this conclusion complies with the role of ERK2 during perfusion studies over collagen [22], where ERK2 phosphorylation can also strictly be coupled to VWF mediated platelet adhesion and activation, rather than to direct collagen–platelet interactions.

In conclusion, the present study, using wild type and TG mice with specific platelet P2X1 gain-of-function, has shown that P2X1 and ERK2 contribute to platelet activation and thrombosis in a shear controlled manner and that ERK2 activation is coupled to platelet GPIb mediated signal transduction predominantly.

Acknowledgements

This work was supported by the FWO Vlaanderen (project nr G.0227.03) and the University of Leuven (project GOA/2004/09). During this study, C.O. was the recipient of a postdoctoral Fellowship from the FWO Vlaanderen and was a Scientific Research Worker FNRS; K.D. received a junior Fellowship from the University Hospital Leuven.

References


